Highlights

  • Group Revenue increased 9% to $42.6 million, supported by a 21% rise in Pain Management revenue.
  • Respiratory revenue declined 15% to $10.9 million, as higher US pricing was offset by softer demand.
  • Statutory NPAT increased to $0.6 million from $0.1 million, while EBIT moved from a $48,000 loss to a $0.2 million profit.
  • Operating cash flow increased $5.8 million to $5.8 million, while free cash flow reached $4.2 million.

Medical Developments International Limited (ASX:MVP) reported FY26 revenue of $42.6 million, an increase of 9% from $39.1 million a year earlier, as higher Pain Management sales offset weaker Respiratory revenue. Net profit after tax increased to $0.6 million from $0.1 million, while EBIT improved to a $0.2 million profit from a $48,000 loss. Medical Developments shares were trading at $0.51, down 0.97%, or $0.005, at 12:16 pm on 20 August 2026.

Pain Management Drives Revenue Growth

Pain Management revenue increased 21% to $31.6 million, representing the main contributor to the group's overall revenue growth. The company reported higher volumes across all markets alongside improved pricing in Australia.

European Pain Management revenue increased 12%, supported by higher volumes sold to European partners. The company said underlying Demand increased and inventory holdings also rose in some markets, partly reflecting the transition of French Supply to a distribution partner from 1 July 2025.

Australian Penthrox revenue increased 16%, with volumes rising 9% and pricing also contributing to the result. Revenue from Rest of World markets increased 66%, although the company attributed much of this movement to the timing of inventory stocking across various markets.

Milestone income also increased to $0.6 million from $0.2 million.

Respiratory Revenue Declines

The Respiratory segment recorded revenue of $10.9 million, down 15% from $12.9 million in FY25. Higher pricing in the US was not sufficient to offset softer demand.

The decline in Respiratory revenue therefore represented a material counterweight to the growth recorded in Pain Management. At group level, however, stronger Penthrox demand and pricing allowed total revenue to increase by $3.5 million year on year.

The company said the effect of lower Respiratory demand was mostly offset by refunds of tariffs paid on imports into the US during FY25 and FY26.

Profitability Improves

Medical Developments recorded statutory NPAT of $0.6 million, compared with a $0.1 million profit in FY25. EBIT improved by $0.3 million, moving from a $48,000 loss to a $0.2 million profit.

The Earnings improvement was linked to stronger Penthrox demand across regions and higher Australian pricing. However, European average selling prices were lower following the shift to partner supply in France and Switzerland.

Foreign exchange movements remained a negative factor. Changes in currency rates reduced earnings by $0.9 million during FY26, compared with a $1.6 million positive contribution in the previous year, with the company attributing much of the current impact to unrealised working-capital losses.

Depreciation and Amortisation was also $0.5 million lower than in FY25.

Cash Flow and Penthrox Expansion

Operating cash flow improved by $5.8 million to $5.8 million, while free cash flow increased by the same amount to $4.2 million. The improvement provides a different earnings perspective from the relatively small statutory profit and reflects the company's improved cash generation during the year.

Penthrox continued to expand across international markets. European in-market demand increased 18% from the prior corresponding period, while volumes in the Australian hospital segment increased 28%.

The company also reported that its transition to capital-light partner distribution in France and Switzerland operated as planned. The Penthrox paediatric label was approved and launched in the UK and across European markets.

Conclusion

Medical Developments entered FY27 with higher group revenue, improved profitability and a substantial increase in cash generation. Pain Management remained the principal growth driver, with Penthrox volumes and Australian pricing supporting the result, while the 15% decline in Respiratory revenue remained a key negative movement. The company also faced a $0.9 million adverse foreign-exchange impact on earnings. International Penthrox demand, the expansion of the paediatric label and the shift towards partner distribution will remain relevant to the company's operating performance as it progresses beyond FY26.